IB Acquisition Corp.
IBAC Nasdaq Services-Commercial Physical & Biological Research Financials FY2023–FY2025
Last close · Oct 23, 2026
$10.86
0.0%What IB Acquisition Corp. does
No business description yet.
- Legal name
- IB Acquisition Corp.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 29, 2025
- Accession · CIK
- 0001493152-25-029365
0001998781
Revenue and margins
IB Acquisition Corp. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
IB Acquisition Corp. returned $106M to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably IB Acquisition Corp. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.8M | $0.4M |
| Current ratio | 0.9x | 1.7x | 0.7x |
| Quick ratio | 0.9x | 1.7x | 0.7x |
| Total assets | $0.1M | $120M | $17.1M |
| Total liabilities | $0.1M | $0.7M | $1.8M |
| Shareholders' equity | −$0.0M | $1.1M | −$0.7M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✓ | ✓ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 5 | — / 5 |
| Accruals ratio | −12.5% | 4.5% | 6.9% |
| Altman Z'' | −2.16 | 1.64 | −1.04 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Operating income | −$0.0M | −$0.5M | −$0.7M |
| Interest expense | — | −$3.0M | — |
| Pretax income | −$0.0M | $2.5M | $4.4M |
| Income tax | — | $0.6M | $1.0M |
| Net income | −$0.0M | $1.9M | $3.4M |
| Cash flow | |||
| Cash from operations | −$0.0M | −$0.8M | −$1.3M |
| Share buybacks | — | — | $106M |
| Dividends and buybacks | — | — | $106M |
| Balance sheet | |||
| Cash and short-term investments | $0.1M | $0.8M | $0.4M |
| Current assets | $0.1M | $1.2M | $1.2M |
| Current liabilities | $0.1M | $0.7M | $1.8M |
| Total assets | $0.1M | $120M | $17.1M |
| Total liabilities | $0.1M | $0.7M | $1.8M |
| Shareholders' equity | −$0.0M | $1.1M | −$0.7M |
| Returns | |||
| Return on capital employed | 125.9% | −0.4% | −4.9% |
| Return on equity | — | 337.6% | 1,587.1% |
| Return on assets | −12.9% | 3.1% | 5.0% |
| Return on tangible equity | — | 168.0% | — |
| Growth | |||
| Net income growth | — | — | 82.9% |
| Financial health | |||
| Current ratio | 0.9x | 1.7x | 0.7x |
| Quick ratio | 0.9x | 1.7x | 0.7x |
| Quality scores | |||
| Altman Z'' | −2.2 | 1.6 | −1.0 |
| Accruals ratio | −12.5% | 4.5% | 6.9% |
Source: SEC EDGAR XBRL filings (CIK 0001998781). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.